T1	Participants 92 148	patients with standard-risk acute lymphoblastic leukemia
T2	Participants 618 698	Children with National Cancer Institute standard-risk ALL were randomly assigned
T3	Participants 478 548	We report the results of a randomized trial of more than 1000 subjects
